BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 18976834)

  • 1. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
    Tintori C; Magnani M; Schenone S; Botta M
    Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors.
    Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M
    Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
    Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors.
    Tuccinardi T; Ortore G; Santos MA; Marques SM; Nuti E; Rossello A; Martinelli A
    J Chem Inf Model; 2009 Jul; 49(7):1715-24. PubMed ID: 19522467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
    Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
    Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
    Chaudhaery SS; Roy KK; Saxena AK
    J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
    Akula N; Lecanu L; Greeson J; Papadopoulos V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
    Patel DS; Bharatam PV
    Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.
    Qin J; Lei B; Xi L; Liu H; Yao X
    Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.